

## Sonpiretigene Isteparvovec for Advanced Retinitis Pigmentosa

### Stakeholder List

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER's outreach or agreed to participate in this review.

- American Council of the Blind
- American Foundation for the Blind
- Curing Retinal Blindness Foundation
- Foundation Fighting Blindness
- Foreseeable Future
- Hope in Focus
- Janssen Pharmaceuticals
- Massachusetts Association for the Blind and Visually Impaired
- Nanoscope Therapeutics
- National Federation of the Blind
- Prevent Blindness
- Research to Prevent Blindness

We spoke with several additional experts in the preparation of this report. Of them, the following individuals have agreed to be identified as having spoken with ICER:

- **Dr. Jacque Duncan, MD**  
Chair, Scientific Advisory Board, Foundation Fighting Blindness  
Chair and Distinguished Professor, Department of Ophthalmology, University of California,  
San Francisco

- **Dr. Zhuo-Hua Pan, PhD**  
Edward T. and Ellen K. Dryer Endowed Professor, Professor of Department of Ophthalmology, Visual and Anatomical Science,  
Scientific Director, Ligon Research Center of Vision  
Kresge Eye Institute, Wayne State University School of Medicine
- **Dr. Mark Pennesi, MD, PhD**  
Professor of Ophthalmology and Molecular and Medical Genetics  
Chief of the Paul H. Casey Ophthalmic Genetics Division  
Casey Eye Institute, School of Medicine at Oregon Health and Science University
- **Dr. Stephen R. Russell, MD**  
Professor, Vitreoretinal Diseases and Surgery Service Director, Dina J. Schrage Professor of Macular Degeneration, University of Iowa

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these individuals or organizations is responsible for the final content of ICER's report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers. For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).